David Siegel
0000-0002-3604-2574
New York University
6 papers found
Refreshing results…
Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial
Sustained Hematopoietic Engraftment Potential after Prolonged Storage of Cryopreserved Hematopoietic Stem Cells Used in Salvage Autologous Stem Cell Transplantation
Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high‐risk multiple myeloma
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma
Prevalence and Survival Impact of Self-Reported Symptom and Psychological Distress Among Patients with Multiple Myeloma
Missing publications? Search for publications with a matching author name.